Floatz Rating
CCC50/100
Confidence
Indicative
Sponsor
Roswell Park Cancer Institute
Modality
UNKNOWN
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
35High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04119830CT.gov Rintatolimod and Pembrolizumab for the Treatment of Refractory Metastatic or Unresectable Colorectal Cancer | — | Withdrawn | — | — | — |
NCT03403634CT.gov Celecoxib, Recombinant Interferon Alfa-2b, and Rintatolimod in Treating Patients With Colorectal Cancer Metastatic to the Liver | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Colorectal Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Rintatolimod (this asset) | Roswell Park Cancer Institute | P2 | CCC · 50 |
| Tipiracil | Mayo Clinic | P2 | BBB |
| Fluorouracilum | City of Hope Medical Center | P4 | BB |
| Oxaliplatin | First Affiliated Hospital of Zhejiang University | P4 | BB |
| Muamycin | City of Hope Medical Center | P3 | BB |
| Capecitabine | First Affiliated Hospital of Zhejiang University | P4 | BB |
| Pentoxifylline | Tanta University | P4 | BB |
| Irinotecan | City of Hope Medical Center | P3 | BB |
| ner1006 | Norgine | P3 | BB |
+42 more in the Colorectal Carcinoma cohort
Other indications for Rintatolimod
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Breast Carcinoma | — | P1/2 | CCC · 54 |
| Breast Cancer | — | P1/2 | CCC · 54 |
| Estrogen-Receptor Negative Breast Cancer | — | P1 | CCC · 52 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Rintatolimod in Colorectal Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/rintatolimod-colorectal-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →